The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome.
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Gefapixant (Primary)
- Indications Interstitial cystitis; Pain
- Focus Therapeutic Use
- Sponsors Afferent Pharmaceuticals
- 09 Oct 2015 Results presented at the 45th Annual Meeting of the International Continence Society
- 26 Feb 2015 According to an Afferent Pharmaceuticals media release, the results of this trial were presented at the 2015 Society of Urodynamics, Female Pelvic Medicine and Urogential Reconstruction Meeting.
- 26 Feb 2015 Results published in an Afferent Pharmaceuticals media release.